Graviton Bioscience

What Graviton Bioscience does

Graviton Bioscience Corporation is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in New York. It develops a portfolio of selective ROCK2 (Rho-associated coiled-coil kinase 2) inhibitors designed to restore cellular homeostasis across fibrotic, autoimmune, and central nervous system (CNS) diseases. The pipeline is anchored by lead candidate GV101 (also referenced as OV888), which is in Phase 1 development for obesity and Cerebral Cavernous Malformations (CCMs), with additional programs targeting Idiopathic Pulmonary Fibrosis, liver fibrosis, endometriosis, Chronic Graft-versus-Host Disease, Myasthenia Gravis, Friedreich's Ataxia, ALS, Alzheimer's Disease, and Progressive Multiple Sclerosis. Beyond the ROCK2 platform, the company has expanded into C6 monoclonal antibodies for neurodegenerative diseases (acquired via Complement Pharma in December 2022) and DYRK1A/DYRK1B kinase inhibitors for diabetes, neurological disorders, and cancers.

The company's core technology is built on an exclusive global license from Beijing Tide for ROCK2 inhibitor chemistry (signed February 2021), supplemented by 20+ filed patents and peer-reviewed mechanistic work, including a Cell Press publication (Hu et al., 2026) on endothelial and perivascular angiocrine ROCK2 in liver fibrosis. The business model is asset-light and licensing-oriented: Graviton advances candidates through early-stage clinical trials and partners with larger pharmaceutical companies for later-stage development and commercialization. Notably, Ovid Therapeutics takes over CCM/orphan CNS programs post-Phase 2, Sino Biopharmaceutical co-develops ROCK2 inhibitors for China, and Sanofi holds a strategic equity stake (February 2024) with collaboration focused on immunology and metabolic syndromes. Graviton is pre-revenue, with cumulative disclosed funding of approximately $74.8M from Pontifax (December 2022), Enavate Sciences (December 2023, $35M), and Sanofi/Enavate (January 2024). The leadership team is led by Founder/CEO Dr. Samuel Waksal (former ImClone Systems and Kadmon Corporation founder, both acquired by Eli Lilly for $7B and Sanofi for $2B respectively) and includes a Nobel laureate (Dr. David MacMillan) on the board. Distribution occurs exclusively through clinical trials and an Expanded Access Program; commercial sales will be handled by pharmaceutical partners upon regulatory approval.

Name

Graviton Bioscience

Legal name

Graviton Bioscience Corporation

Website

https://gravitoncorp.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Graviton Bioscience is a clinical-stage biotech developing selective ROCK2 inhibitors, C6 antibodies, and DYRK kinase inhibitors to treat fibrotic, autoimmune, CNS, and metabolic diseases, advancing candidates through early trials and partnering with larger pharmaceutical companies for later-stage development and commercialization.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

Keywords

• Clinical stage biotech
• ROCK2 inhibitors
• Fibrotic disease therapy
• Autoimmune disease drugs
• CNS drug development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Licensing: Pre-revenue biotech company focused on developing novel therapies through clinical trials. Revenue model will likely involve licensing agreements and commercialization partnerships with larger pharmaceutical companies, as evidenced by Ovid Therapeutics handling commercialization post-Phase 2.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Graviton Bioscience is a clinical-stage biopharmaceutical company developing a portfolio of selective ROCK2 inhibitors and complementary targeted therapies (C6 antibodies, DYRK kinase inhibitors) to restore cellular homeostasis in patients with fibrotic, autoimmune, and CNS diseases. The lead candidate GV101 (OV888) is being advanced into clinical trials for obesity, Cerebral Cavernous Malformations (CCMs), GvHD, and other indications, with late-stage development and commercialization handed off to pharmaceutical partners.

Product overview

Graviton Bioscience is a biopharmaceutical company pioneering selective ROCK2 inhibitors for treating fibrotic, autoimmune, and CNS diseases. The core portfolio includes GV101 (ROCK2 inhibitor, also known as OV888) in clinical development for obesity and Cerebral Cavernous Malformations; a broader ROCK2 inhibitor platform targeting multiple indications including Chronic GvHD, Friedreich's Ataxia, Myasthenia Gravis, Idiopathic Pulmonary Fibrosis, Endometriosis, ALS, Alzheimer's Disease, and Progressive MS; C6 antibody therapeutics for neurodegenerative diseases; and DYRK inhibitors for kinase-related conditions. The company operates through strategic partnerships with Ovid Therapeutics (CCM commercialization), Sino Biopharmaceutical (clinical program advancement), and Sanofi (equity investment and development collaboration).

Differentiator

Problem solved

Functional benefit

Products and services

• GV101 (also known as OV888) Selective ROCK2 inhibitor (lead clinical candidate) in development for obesity, Cerebral Cavernous Malformations (CCMs), Chronic Graft-versus-Host Disease, and other fibrotic, autoimmune, and CNS indications. Promotes healthier weight loss by reducing fat while preserving muscle mass.
• ROCK2 Inhibitors Portfolio Portfolio of selective ROCK2 inhibitors targeting fibrotic, autoimmune, and CNS diseases across multiple organ systems, including indications such as Chronic GvHD, Friedreich's Ataxia, Myasthenia Gravis, Idiopathic Pulmonary Fibrosis, Endometriosis, ALS, Alzheimer's Disease, and Progressive Multiple Sclerosis.
• C6 Monoclonal Antibody Specially designed antibody targeting the C6 complement component to control its activity in the complement system immune defense, being developed as a potential therapy for neurodegenerative diseases including myasthenia gravis and ALS.
• DYRK1A/DYRK1B Kinase Inhibitors Targeted inhibitors for DYRK (dual-specificity tyrosine phosphorylation-regulated kinase) family kinases, specifically DYRK1A and DYRK1B, intended to recalibrate abnormal kinase activity implicated in type 1 diabetes, neurological disorders, and cancers.

Quantifiable outcome

• Phase 1 clinical trial completed for OV888/GV101 Capsule showing topline data
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Sino Biopharmaceutical LimitedcoreStrategic or Co-development Partner · 1 January 2024Long-term partnership with Chinese pharmaceutical company Sino Biopharmaceutical for ROCK2 inhibitors development. ROCK2 is involved in several diseases including fibrotic, autoimmune and CNS diseases. Clinical programs planned with further investigation in 2024.
• Ovid TherapeuticscoreStrategic or Co-development Partner · 1 May 2023Strategic alliance to accelerate development of novel ROCK2 inhibitors targeting Cerebral Cavernous Malformations (CCMs) and orphan CNS indications. Graviton advances candidates through Phase 2 clinical trials, after which Ovid spearheads commercialization efforts to deliver treatments to patients affected by CCMs and other orphan CNS diseases.
• Beijing TidecoreOEM/ Whitelabel/ Licensing Partner · 23 February 2021Global licensing agreement for ROCK2 inhibitor technology from Beijing Tide, enabling Graviton to develop and commercialize ROCK2 inhibitors globally.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Strategic equity investor in Graviton and owner of Kadmon's ROCK2 assets. A large incumbent pharma with overlapping immunology and metabolic pipelines that could either partner with or competitively position against Graviton.
• Bristol Myers Squibb: Large pharma that developed and commercializes belumosudil (REZUROCK), the only approved selective ROCK2 inhibitor for chronic GvHD. Direct competitive benchmark for Graviton's ROCK2 programs, particularly in autoimmune indications.
• Vertex Pharmaceuticals: Large biotech with growing presence in CNS, rare diseases, and small-molecule drug development. Relevant comparable for valuation benchmarking and orphan CNS commercial strategy.
• AbbVie: Large incumbent pharma with deep autoimmune and fibrosis franchises (e.g., HUMIRA, Skyrizi). A natural strategic acquirer or competitor for any successful ROCK2 fibrosis or autoimmune asset.

Emerging players

• Palisade Bio: Smaller clinical-stage biotech developing selective ROCK inhibitors for fibrotic and inflammatory diseases. Direct mechanistic competitor with overlapping fibrosis and immunology focus.
• Atea Pharmaceuticals: Similar-sized clinical-stage biotech with single-mechanism focus and pharmaceutical partnership model. Comparable scale, stage, and capital structure for benchmarking.

Direct peers

• Ovid Therapeutics: Strategic partner commercializing Graviton's CCM and orphan CNS programs post-Phase 2. Operates in the same rare CNS disease space and shares development risk and economics on the lead asset.
• ChemoCentryx: Was a clinical-stage autoimmune biotech with a similar small-team, mechanism-driven approach before its $4B acquisition by Amgen for Tavneos. Comparable in scale, therapeutic focus, and exit trajectory.
• MeiraGTx: Gene therapy biotech also founded by Samuel Waksal. Comparable founder-driven clinical-stage biotech with multi-platform approach and CNS/orphan disease focus.
• Kadmon Corporation: Pre-acquisition Kadmon was the most direct ROCK2-focused peer, founded and led by the same CEO (Samuel Waksal) before its $2B acquisition by Sanofi. Its clinical pipeline and selective ROCK2 mechanism are the closest historical analog to Graviton.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/graviton-bioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graviton Bioscience